Evidence map›Paper›PMID 30788128›Full record

ArticleUnited European gastroenterology journal2019

Haemostasis and prevention of bleeding related to ER: The role of a novel self-assembling peptide.

Sharmila Subramaniam, Kesavan Kandiah, Sreedhari Thayalasekaran, Gaius Longcroft-Wheaton, Pradeep Bhandari

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in United European gastroenterology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05581173 (Multicenter Prospective Evaluation of the Efficacy of a Self-Assembling Matrix Forming Gel to Prevent Stricture Formation in High-Risk Patients), which is not on this map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05581173 completednot on this mapstarted 2022, after this paper: background citation

Multicenter Prospective Evaluation of the Efficacy of a Self-Assembling Matrix Forming Gel to Prevent Stricture Formation in High-Risk Patients

Typeobservational_patient_registrySponsorAdventHealthRan2022 to 2025Enrolled41ConditionsEsophageal Stricture, StrictureArmsPurastat SAP gel application
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Hemostasis: Role of PuraStatWorld journal of gastrointestinal endoscopy · 2025
    Article
  11. Article
  12. Review
  13. Efficacy and applications for PuraStatWorld journal of gastrointestinal endoscopy · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sharmila SubramaniamDepartment of Gastroenterology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Kesavan KandiahDepartment of Gastroenterology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Sreedhari ThayalasekaranDepartment of Gastroenterology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Gaius Longcroft-WheatonDepartment of Gastroenterology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Pradeep BhandariDepartment of Gastroenterology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Portsmouth Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Endoscopic resection is now commonly used for removal of early gastrointestinal lesions. However, the risk of the procedure may be heightened by intraprocedural or delayed bleeding. A novel, self-assembling peptide (PuraStat®) was recently licensed for use as a haemostat. Objective: The aim of this study was to assess the efficacy and safety of this haemostat when used to control intraprocedural bleeding or to prevent delayed bleeding in endoscopic resection. Methods: PuraStat® was used on 100 patients undergoing endoscopic resection in a tertiary referral centre. The efficacy, safety, feasibility of use and delayed bleeding rates were measured. Results: Forty-eight oesophageal, 31 colorectal, 11 gastric and 10 duodenal procedures were included. The mean lesion size was 3.7 cm and 30% of the patients were on antithrombotic therapy. Intraprocedural bleeding occurred in 64%. PuraStat® was an effective haemostat in 75% of these cases. Only a small amount was required for haemostasis (mean = 1.76 ml) and it took on average 69.5 seconds to stop a bleed. The delayed bleeding rate was 3%. Conclusions: PuraStat® is an effective haemostat for use in controlling bleeds during endoscopic resection. It is safe, easy to use and did not interfere with the procedure.

Indexed as

Hemostatic TechniquesAgedAged, 80 and overEndoscopic Mucosal ResectionEndoscopy, GastrointestinalFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPeptidesTreatment OutcomePeptidesDelayed bleedingendoscopic mucosal resectionendoscopic submucosal dissectionhaemostasisself-assembling peptide

Identifiers

PMID30788128
PMCPMC6374844
OpenAlexW2900054606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.